FibroGen (NASDAQ: FGEN)
FibroGen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
FibroGen Company Info
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
News & Analysis
Investing in Biotech ETFs
Here are the five best biotech ETFs to invest in right now.
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
Its pipeline is looking thin, and it might hit another speed bump quite soon.
Why FibroGen Fell by More Than 9% on Wednesday
A noted investment bank takes a dimmer view of the company's stock.
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
FDA approval of roxadustat seems unlikely.
Here's Why FibroGen Stock Is Plunging Today
An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns.
Why FibroGen Stock Is Crashing Today
The company disclosed a bombshell related to its safety results for lead candidate roxadustat.
Why FibroGen Got Mashed on Monday
The FDA delivered a discouraging update in time for the holidays.
FibroGen's Anemia Drug Goes to FDA for Review
A decision on Roxadustat should arrive by Dec. 20.
Valuation
Earnings Transcripts
FibroGen, inc (FGEN) Q3 2021 Earnings Call Transcript
FGEN earnings call for the period ending September 30, 2021.
FibroGen, inc (FGEN) Q2 2021 Earnings Call Transcript
FGEN earnings call for the period ending June 30, 2021.
FibroGen Inc (FGEN) Q1 2021 Earnings Call Transcript
FGEN earnings call for the period ending March 31, 2021.
FibroGen Inc (FGEN) Q4 2020 Earnings Call Transcript
FGEN earnings call for the period ending January 31, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.